SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme
August 07 2008 - 9:00AM
PR Newswire (US)
DUBLIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery,
rapid development and commercialization of therapies for solid
tumors and hematological malignancies, today announced that the
U.S. Food and Drug Administration (FDA) has granted orphan drug
designation for the company's lead drug candidate, MP-470, for the
treatment of glioblastoma multiforme (GBM), an often fatal form of
brain cancer. The FDA accepted SuperGen's application upon review
of data from in vitro studies in glioblastoma cell lines that
demonstrate that either MP-470 or ionizing radiation (IR) alone
induce cell death, but when used in combination they
synergistically increase cell death by more than two-fold over
either agent alone. MP-470 is currently being evaluated in phase 1
trials as a single agent and in combination with chemotherapy in
patients with solid tumors, and a phase 1b study in patients with
GBM is planned. "Glioblastoma is the most common malignant primary
brain tumor, representing approximately 10% of all brain tumors,"
said Gregory Berk, MD, SuperGen's Chief Medical Officer. "This
designation not only underscores the need for improved therapies in
GBM, it also underscores the company's development strategy in
pursuing areas of unmet need." About MP-470 MP-470 is an oral,
selective multi-targeted tyrosine kinase inhibitor that suppresses
c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. MP470
also suppresses Rad51 protein, a critical component of
double-stranded DNA repair in cancer cells. Preclinical testing of
MP-470 has identified anti- tumor activity against a wide spectrum
of cancers. About Glioblastoma Multiforme GBM, also known as grade
IV astrocytoma, is the most common and aggressive malignant brain
tumor in adults. Brain tumors are the second leading cause of
cancer-related deaths in males ages 20-39 and the fifth leading
cause of cancer-related deaths in women ages 20-39. Approximately
50,000 cases of primary central nervous system (CNS) cancers are
diagnosed each year in the United States, of which 22,000 are
malignant tumors. More than 35,000 Americans have GBM, which
accounts for approximately 52% of all primary malignant brain
tumors, and approximately 13,000 will die each year from the
disease. The tumor forms in the glial (supportive) tissue of the
brain and invades adjacent tissue. The tumor cells do not spread
throughout the body and symptoms are caused by the tumor invading
the brain. Surgery is generally the first line of treatment,
followed by radiation therapy and chemotherapy, either individually
or in combination. Although primary treatment is often successful
in temporarily stopping the progression of the tumor, glioblastoma
multiforme tumors almost always recur and survival rates remain
low. Thus the disease remains a significant unmet clinical need in
oncology. About Orphan Drug Designation "Orphan drug" is a
designation by the FDA indicating a therapy developed to treat rare
diseases affecting fewer than 200,000 persons in the United States.
Orphan drug designation entitles SuperGen to seven years of market
exclusivity for MP-470 in the treatment of patients with GBM.
Additional incentives include potential tax credits related to
certain clinical trial expenses, a possible exemption from the FDA
user fee, and assistance in clinical trial protocol design. About
SuperGen Based in Dublin, Calif., SuperGen, Inc. is a
pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies. SuperGen is developing a number of
therapeutic anti-cancer products focused on kinase and cell
signaling inhibitors and DNA methyltransferase inhibitors. For more
information about SuperGen, please visit http://www.supergen.com/.
Forward-Looking Statements This news release contains certain
"forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are
typically preceded by words such as "believes," "expects,"
"anticipates," "intends," "will," "may," "should," or similar
expressions. These forward-looking statements are not guarantees of
future performance and involve a number of risks and uncertainties
that may cause actual results to differ materially from the results
discussed in these statements. Factors that might cause the
company's results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to, the ability to discover, develop and move target
compounds into clinical development and other risks and
uncertainties detailed from time to time in the company's filings
with the Securities and Exchange Commission including its most
recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no
duty to update any of these forward-looking statements to conform
them to actual results. Contacts: Timothy L. Enns SuperGen, Inc.
SVP, Corporate Communications & Business Development Tel: (925)
560-0100 E-mail: Mary M. Vegh SuperGen, Inc. Manager, Investor
Relations Tel: (925) 560-2845 E-mail: DATASOURCE: SuperGen, Inc.
CONTACT: Timothy L. Enns, SVP, Corporate Communications &
Business Development, +1-925-560-0100, , or Mary M. Vegh, Manager,
Investor Relations, +1-925-560-2845, , both of SuperGen, Inc. Web
site: http://www.supergen.com/
Copyright
Supergen, Inc. (MM) (NASDAQ:SUPG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Supergen, Inc. (MM) (NASDAQ:SUPG)
Historical Stock Chart
From Oct 2023 to Oct 2024